Phase I Trial of PX-478

计划入组 45 人 · 首次发布于 2007 年 8 月 30 日

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

计划入组 39 人 · 首次发布于 2011 年 8 月 3 日

Phase I Trial of Oral PX-866

计划入组 90 人 · 首次发布于 2008 年 8 月 1 日

PX-329

PX-102

C₂₉H₂₂Cl₃NO₄

PX-1041

TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell Renal Cell Carcinoma

Heidelberg Pharma Secures $45 Million Through Modified Licensing Agreement with HealthCare Royalty and Soleus Capital

Heidelberg Pharma Advances Novel ATAC Technology Platform with Multiple Cancer Candidates in Clinical Development